A Phase 1 interventional study of Navlimetostat and Itraconazole in Healthy Female Adults, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Navlimetostat · Drug: Itraconazole
Drug: Navlimetostat · Drug: Rifampin
Drug: Navlimetostat · Drug: Midazolam
Drug: Navlimetostat
Drug: Navlimetostat · Drug: Pantoprazole
Specified dose on specified days
Also known as: BMS-986504, MRTX-1719
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Maximum observed concentration (Cmax) of Navlimetostat
Part 1A, Part 1B, Part 3, Part 4
Time frame: Up to approximately 3 weeks
Area under the concentration-time curve from time zero to 192 hours (AUC(0-192)) of Navlimetostat
Part 1A
Time frame: Up to approximately 3 weeks
(AUC(INF)) of Navlimetostat with the coadministration of itraconazole
Part 1A
Time frame: Up to approximately 3 weeks
AUC(INF) of Navlimetostat without the coadministration of itraconazole
Part 1A
Time frame: Up to approximately 3 weeks
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Navlimetostat
Part 1B, Part 3, Part 4
Time frame: Up to approximately 3 weeks
AUC(INF) of Navlimetostat with the coadministration of Rifampin
Part 1B
Time frame: Up to approximately 3 weeks
AUC(INF) of Navlimetostat without the coadministration of Rifampin
Part 1B
Time frame: Up to approximately 3 weeks
Cmax of Midazolam
Part 2
Time frame: Up to approximately 3 weeks
AUC(0-T) of Midazolam
Part 2
Time frame: Up to approximately 3 weeks
AUC(INF) of Midazolam with the coadministration of Navlimetostat
Part 2
Time frame: Up to approximately 3 weeks
AUC(INF) of Midazolam without the coadministration of Navlimetostat
Part 2
Time frame: Up to approximately 3 weeks
AUC(INF) of Navlimetostat with a high fat meal
Part 3
Time frame: Up to approximately 3 weeks
AUC(INF) of Navlimetostat without a high fat meal
Part 3
Time frame: Up to approximately 3 weeks
AUC(INF) of Navlimetostat with the coadministration of Pantoprazole
Part 4
Time frame: Up to approximately 3 weeks
AUC(INF) of Navlimetostat without the coadministration of Pantoprazole
Part 4
Time frame: Up to approximately 3 weeks
Drug-related AEs
Time frame: Up to approximately 6 weeks
Adverse events (AEs)
Time frame: Up to approximately 6 weeks
Serious adverse events (SAEs)
Time frame: Up to approximately 6 weeks
AEs leading to discontinuation of study or study intervention
Time frame: Up to approximately 6 weeks
Number of participants with clinically significant changes in physical examination (PE)
Time frame: Up to approximately 6 weeks
Number of participants with clinically significant changes in vital signs (VS)
Time frame: Up to approximately 6 weeks
Number of participants with clinically significant changes in 12-lead electrocardiograms (ECGs)
Time frame: Up to approximately 6 weeks
Number of participants with clinically significant changes in clinical laboratory test results
Time frame: Up to approximately 6 weeks
AUC(0-T) of Navlimetostat
Part 1A
Time frame: Up to approximately 3 weeks
Time of maximum observed concentration (Tmax) of Navlimetostat
Part 1A, Part 1B, Part 3, Part 4
Time frame: Up to approximately 3 weeks
Half-life (T-HALF) of Navlimetostat
Part 1A, Part 1B, Part 3, Part 4
Time frame: Up to approximately 3 weeks
Apparent total body clearance (CLT/F) of Navlimetostat
Part 1A, Part 1B, Part 3, Part 4
Time frame: Up to approximately 3 weeks
Apparent volume of distribution at terminal phase (Vz/F) of Navlimetostat
Part 1A, Part 1B, Part 3, Part 4
Time frame: Up to approximately 3 weeks
Tmax of Midazolam
Part 2
Time frame: Up to approximately 3 weeks
T-HALF of Midazolam
Part 2
Time frame: Up to approximately 3 weeks
CLT/F of Midazolam
Part 2
Time frame: Up to approximately 3 weeks
Vz/F of Midazolam
Part 2
Time frame: Up to approximately 3 weeks
Cmax of Navlimetostat Metabolite
Time frame: Up to approximately 3 weeks
AUC(0-T) of Navlimetostat Metabolite
Time frame: Up to approximately 3 weeks
AUC(INF) of Navlimetostat Metabolite
Time frame: Up to approximately 3 weeks
AUC(0-192) of Navlimetostat Metabolite
Part 1A
Time frame: Up to approximately 3 weeks
AUC(0-24) of Navlimetostat Metabolite
Part 2
Time frame: Up to approximately 3 weeks
Tmax of Navlimetostat Metabolite
Time frame: Up to approximately 3 weeks
T-HALF of Navlimetostat Metabolite
Time frame: Up to approximately 3 weeks
Mean ratio (MR)_Cmax of Navlimetostat Metabolite
Time frame: Up to approximately 3 weeks
MR_AUC(0-T) of Navlimetostat Metabolite
Time frame: Up to approximately 3 weeks
MR_AUC(INF) of Navlimetostat Metabolite
Time frame: Up to approximately 3 weeks
MR_AUC(0-192) of Navlimetostat Metabolite
Part 1A
Time frame: Up to approximately 3 weeks
MR_AUC(0-24) of Navlimetostat Metabolite
Part 2
Time frame: Up to approximately 3 weeks
Cmax of Rifampin
Part 1A and Part 1B
Time frame: Up to approximately 3 weeks
Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of Rifampin
Part 1A and Part 1B
Time frame: Up to approximately 3 weeks
Trough observed concentration (Ctrough) of Rifampin
Part 1A and Part 1B
Time frame: Up to approximately 3 weeks
Tmax of Rifampin
Part 1A and Part 1B
Time frame: Up to approximately 3 weeks
Cmax of 1-hydroxymidazolam
Part 2
Time frame: Up to approximately 3 weeks
AUC(0-T) of 1-hydroxymidazolam
Part 2
Time frame: Up to approximately 3 weeks
AUC(INF) of 1-hydroxymidazolam
Part 2
Time frame: Up to approximately 3 weeks
Tmax of 1-hydroxymidazolam
Part 2
Time frame: Up to approximately 3 weeks
T-HALF of 1-hydroxymidazolam
Part 2
Time frame: Up to approximately 3 weeks
MR_Cmax of 1-hydroxymidazolam
Part 2
Time frame: Up to approximately 3 weeks
MR_AUC(0-T) of 1-hydroxymidazolam
Part 2
Time frame: Up to approximately 3 weeks
MR_AUC(INF) of 1-hydroxymidazolam with the coadministration of Navlimetostat
Part 2
Time frame: Up to approximately 3 weeks
MR_AUC(INF) of 1-hydroxymidazolam without the coadministration of Navlimetostat
Part 2
Time frame: Up to approximately 3 weeks
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Navlimetostat